Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MasterKey-01 study of BDTX-189 in advanced solid tumors
MOH_2021-07-12_009903Phase 2Completed
- Sponsor
- Black Diamond Therapeutics
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tuxobertinib in Nonhematologic neoplasms, sponsored by Black Diamond Therapeutics. Primary endpoint: Not specified. Started Apr 2021; status: completed.
02
Drugs
tuxobertinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on MOH_2021-07-12_009903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-07-12_009903.